April 2, 2019
Centogene names new board members
Centogene has appointed Dr. Flemming Ornskov to the Supervisory Board and he has also been elected Non-Executive Chairman, effective April 1, 2019.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 2, 2019
Johnson & Johnson buy Auris Health for $3.4B, plus milestons payments
Johnson & Johnson has bought Auris Health, Inc. for about $3.4 billion in cash, with additional payments of up to $2.35 billion, in the aggregate, which may be payable upon reaching certain predetermined milestones, JJ said in a statement Monday.
April 2, 2019
Novartis’ Cosentyx approved in China for adult psoriasis patients
Novartis got approval from the China Health Authority NMPA for
Cosentyx, its the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
April 2, 2019
Molecular Partners, Allergan to file abicipar BLA in USA in the first half of 2019
Allergan and Molecular Partners revealed Tuesday the topline safety results from MAPLE, study which enrolled 123 age-related Neovascular Macular Degeneration (nAMD) patients and evaluated the safety of abicipar produced via a modified manufacturing process, which showed lower incidence and type of IOI.
April 2, 2019
CDISC to Develop Data Standards for Crohn’s Disease With Support from the Helmsley Charitable Trust
AUSTIN, Texas & NEW YORK–(BUSINESS WIRE)–CDISC will develop the first global, non-proprietary clinical data standards for Crohn’s disease with a…
April 2, 2019
Global Retinoblastoma Treatment Market Study, 2019: Outlook to 2024 – Non-hereditary Retinoblastoma Expected to Maintain Its Dominance – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinoblastoma Treatment Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering.…
April 2, 2019
Vertex Appoints Charles Wagner as Chief Financial Officer
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief…
April 2, 2019
X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the…
April 2, 2019
Axcella Announces Patent Issuance for AXA™ Candidate AXA1125 Methods of Use
Patent issuance from Axcella’s broad Endogenous Metabolic Modulator (EMM) portfolio Claims cover methods of use of EMM compositions in liver…
April 2, 2019
Ocular Therapeutix™ Announces Notification of FDA Acceptance of Supplemental New Drug Submission for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
PDUFA Target Action Date Set for November 10, 2019 BEDFORD, Mass.–(BUSINESS WIRE)—-Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused…